NAPROXEN SODIUM Drug Patent Profile

When do Naproxen Sodium patents expire, and what generic alternatives are available?

Naproxen Sodium is a drug marketed by Bionpharma, Catalent, Onesource Specialty, Patheon Softgels, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hetero Labs Ltd V, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Novelgenix Theraps, Perrigo, Pharmobedient, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sciegen Pharms, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, Yichang Humanwell, Amneal Pharms Co, Corepharma, Granules, P And L, Perrigo R And D, and Aurobindo Pharma. and is included in forty-eight NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in thirteen countries.

The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naproxen Sodium

A generic version of NAPROXEN SODIUM was approved as naproxen sodium; pseudoephedrine hydrochloride by PERRIGO on March 17^th, 2004.

Summary for NAPROXEN SODIUM

International Patents:	15
US Patents:	5
Applicants:	40
NDAs:	48
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NAPROXEN SODIUM

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAPROXEN SODIUM	Capsules	naproxen sodium	200 mg	021920	1	2017-11-15

US Patents and Regulatory Information for NAPROXEN SODIUM

NAPROXEN SODIUM is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granules	NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride; naproxen sodium	TABLET;ORAL	213663-001	Sep 24, 2020		OTC	No	No
Novelgenix Theraps	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	207612-001	Nov 16, 2018		DISCN	No	No
Hamilton Pharms	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074106-001	Aug 31, 1993		DISCN	No	No
Purepac Pharm	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074319-002	Mar 20, 1995		DISCN	No	No
Teva	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074198-001	Dec 21, 1993		DISCN	No	No
Pld Acquisitions Llc	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	074646-001	Jan 13, 1997		DISCN	No	No

International Patents for NAPROXEN SODIUM

See the table below for patents covering NAPROXEN SODIUM around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	1863458
Slovenia	1863458
European Patent Office	3061447	SYSTÈME DE SOLVANT DESTINÉ À AMÉLIORER LA SOLUBILITÉ D'AGENTS PHARMACEUTIQUES (SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS)
Mexico	2007011039	SISTEMA DE SOLVENTE PARA AUMENTAR LA SOLUBILIDAD DE AGENTES FARMACEUTICOS. (SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS.)
Denmark	1863458
Hungary	E030784

Supplementary Protection Certificates for NAPROXEN SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105

Naproxen Sodium: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, inflammation, and fever. Its patent protection has long expired, leading to a highly genericized market dominated by price-competitive manufacturers. Investment opportunities lie not in proprietary innovation but in efficient production, supply chain management, and market access for generics.

What is the Current Patent Status of Naproxen Sodium?

The original patents covering naproxen sodium, including its synthesis and therapeutic uses, have expired. The key patent, U.S. Patent No. 3,904,687, which claimed a novel synthesis of naproxen, expired in 1993. Other related patents covering specific formulations or manufacturing processes have also expired or are nearing expiration. This lack of active patent protection means any company can manufacture and sell naproxen sodium without licensing fees to the original innovators.

• Original Composition of Matter Patents: Expired.
• Key Synthesis Patents: Expired (e.g., U.S. Patent No. 3,904,687).
• Formulation Patents: Largely expired or of limited scope.

The absence of new patentable subject matter for naproxen sodium itself has shifted competition to other areas.

Who are the Major Manufacturers of Naproxen Sodium?

The market for naproxen sodium is characterized by a large number of generic manufacturers globally. Leading players often compete on volume and cost efficiency.

• Major Generic Manufacturers:
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V. (now Viatris Inc.)
  • Perrigo Company plc

These companies leverage their scale, established manufacturing capabilities, and global distribution networks to serve a broad customer base, including retailers, wholesalers, and other pharmaceutical companies. Competition is primarily driven by the cost of goods sold and the ability to secure market share through competitive pricing.

What are the Market Dynamics for Naproxen Sodium?

Naproxen sodium operates within the mature and highly competitive over-the-counter (OTC) and prescription generic drug markets. Demand is relatively stable, driven by its established efficacy for common pain and inflammatory conditions.

• Market Size: The global NSAID market, of which naproxen sodium is a significant component, is valued in the billions of dollars. However, segmenting the precise market share for naproxen sodium specifically is challenging due to its generic nature and inclusion within broader NSAID category reporting. Projections indicate a compound annual growth rate (CAGR) for the NSAID market generally between 4% and 6% [1].
• Key Market Drivers:
  • Prevalence of chronic pain and inflammatory conditions.
  • Aging global population.
  • Cost-effectiveness compared to newer, branded analgesics.
  • Widespread availability and physician familiarity.
• Market Restraints:
  • Intense price competition among generic manufacturers.
  • Availability of alternative pain relief options (acetaminophen, ibuprofen, prescription drugs).
  • Concerns regarding long-term NSAID use (gastrointestinal, cardiovascular risks).
  • Regulatory hurdles for new generic approvals.

The OTC segment remains the largest volume driver, with brands like Aleve (a naproxen sodium product) having established significant consumer recognition, even within a genericized market.

What are the Regulatory Considerations for Naproxen Sodium?

Naproxen sodium is approved for sale by regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Good Manufacturing Practices (GMP) and maintain robust quality control systems.

• FDA Approval: Generic naproxen sodium products must demonstrate bioequivalence to the reference listed drug (RLD).
• GMP Compliance: Manufacturers are subject to regular inspections to ensure adherence to quality and safety standards.
• Labeling Requirements: Product labeling must comply with regulatory guidelines, including indications, dosage, warnings, and precautions.
• Post-Market Surveillance: Manufacturers are responsible for monitoring and reporting adverse events.

The regulatory landscape for generics is well-established, with a clear pathway for approval for manufacturers meeting the required standards.

What are the Opportunities for Investment in Naproxen Sodium?

Given the patent-expired status, direct investment in naproxen sodium innovation is unlikely. Opportunities exist in areas that enhance the profitability of generic manufacturing and distribution.

• Manufacturing Efficiency: Investments in state-of-the-art, cost-efficient manufacturing facilities can provide a competitive edge. Automation, process optimization, and supply chain integration are key.
• Supply Chain Management: Companies that can secure reliable, low-cost raw material sourcing and manage complex global logistics will gain market share. Vertical integration, from active pharmaceutical ingredient (API) production to finished dosage forms, can be advantageous.
• Market Access and Distribution: Partnerships with large retailers, pharmacy benefit managers (PBMs), and hospital systems can secure significant sales volumes. Developing strong distribution networks in emerging markets also presents growth potential.
• Portfolio Expansion: Manufacturers with a broad portfolio of generic NSAIDs and other pain management products can achieve economies of scale and cross-selling opportunities.
• API Production: Investment in API manufacturing facilities can provide a cost advantage and supply security for finished dosage form manufacturers, or serve as a distinct business line for API suppliers.

Companies focused on operational excellence and market penetration are best positioned to succeed in this segment.

What are the Risks Associated with Naproxen Sodium Investment?

The primary risks stem from the highly competitive and price-sensitive nature of the generic drug market.

• Price Erosion: Intense competition leads to continuous downward pressure on prices, impacting profit margins.
• Raw Material Cost Volatility: Fluctuations in the cost of chemical precursors for naproxen synthesis can affect profitability.
• Regulatory Changes: New or evolving regulatory requirements can increase compliance costs or restrict market access.
• Competition from Newer Therapies: Development of novel pain management drugs with improved efficacy or safety profiles could reduce demand for older NSAIDs.
• Genericization of Branded Products: When branded NSAIDs lose patent protection, they become generic, intensifying competition.
• Quality Control Failures: Manufacturing defects or quality issues can lead to product recalls, regulatory penalties, and significant reputational damage.

These risks require robust risk management strategies, including diversified product portfolios and stringent quality assurance.

Key Takeaways

Naproxen sodium is a mature, genericized pharmaceutical product with no active patent protection for its core composition or primary uses. Investment opportunities are focused on operational efficiency, supply chain optimization, and market access rather than novel R&D. The market is characterized by intense price competition among a large number of generic manufacturers. Risks include significant price erosion, raw material cost fluctuations, and potential competition from newer therapies. Companies demonstrating manufacturing excellence and strong distribution capabilities are best positioned for success.

Frequently Asked Questions

1. Are there any emerging patentable innovations related to naproxen sodium that could create new market exclusivity? While the core naproxen sodium molecule is off-patent, research into novel delivery systems, combination therapies, or improved manufacturing processes could theoretically lead to new patentable intellectual property. However, the economic incentive for such innovation in a mature generic market is generally low compared to developing entirely new drug entities.

2. What is the typical profit margin for a generic naproxen sodium manufacturer? Profit margins for generic naproxen sodium are generally low, often in the single digits to low double digits percentage range, due to intense price competition. This contrasts sharply with margins for novel, branded pharmaceuticals.

3. How does the regulatory approval process for generic naproxen sodium compare to a new molecular entity? The approval process for generic naproxen sodium is significantly less complex and faster than for a new molecular entity. Generics require demonstration of bioequivalence to an approved reference drug and compliance with manufacturing standards, whereas new drugs require extensive preclinical and clinical trials to prove safety and efficacy.

4. What are the primary geographical markets for naproxen sodium sales? The primary markets are North America, Europe, and Asia, driven by established healthcare systems, large populations, and high prevalence of pain and inflammatory conditions. However, significant sales also occur in other regions as generic access expands.

5. Can an investment in a naproxen sodium manufacturer provide significant growth potential? Direct growth from naproxen sodium sales alone is limited due to market maturity and price pressures. Growth potential for a manufacturer is typically achieved through expanding their overall generic portfolio, increasing manufacturing efficiency to capture market share, or through strategic acquisitions.

Citations

[1] Global Market Insights. (2023). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size, Share & Trends Analysis Report.